The Diagnostic Accuracy of Claudin-4 Immunochemistry in Differentiating Metastatic Carcinomas From Mesothelial Processes in Serous Effusion Cytology: A Systematic Review and Meta-analysis.


Journal

Archives of pathology & laboratory medicine
ISSN: 1543-2165
Titre abrégé: Arch Pathol Lab Med
Pays: United States
ID NLM: 7607091

Informations de publication

Date de publication:
14 Jun 2024
Historique:
accepted: 03 05 2024
medline: 14 6 2024
pubmed: 14 6 2024
entrez: 13 6 2024
Statut: aheadofprint

Résumé

Distinguishing metastatic carcinomas from mesotheliomas or reactive mesothelial cells in pleural, peritoneal, and pericardial effusions is a common diagnostic problem cytopathologists encounter. To perform the first meta-analysis on the pooled diagnostic accuracy of claudin-4 immunochemistry in serous effusion cytopathology. This report followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for diagnostic test accuracy studies. Three databases (PubMed, Scopus, and the Cochrane Library) were searched until October 9, 2023, followed by study selection using specific inclusion and exclusion criteria and data extraction. The study quality assessment was performed by using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Statistical analysis was performed by using R to calculate the pooled sensitivity and specificity of claudin-4 immunochemistry. In addition, the diagnostic odds ratio was measured, representing the odds ratio of a positive result indicating a carcinoma rather than a mesothelial process in serous effusion cytology. Fourteen observational studies, published between 2011 and 2023, fulfilled the selection criteria and were included. All 14 studies used the 3E2C1 clone. Claudin-4 immunochemistry showed a high diagnostic accuracy in serous effusion cytology. The pooled sensitivity and specificity were 98.02% (95% CI, 93.96%-99.37%) and 99.72% (95% CI, 97.36%-99.97%), respectively. Lastly, the pooled diagnostic odds ratio was 1660.5 (95% CI, 760.0-3627.8) and no evidence of statistical heterogeneity between the included studies was found (I2 = 0%, τ2 = 0). Claudin-4 may be used as a single pan-carcinoma immunochemical biomarker in the differential diagnosis between metastatic carcinomas and mesotheliomas or reactive mesothelial cells in serous effusion cytology.

Identifiants

pubmed: 38871358
pii: 501364
doi: 10.5858/arpa.2023-0560-RA
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 College of American Pathologists.

Auteurs

Maria Kleinaki (M)

From School of Medicine, European University Cyprus, Nicosia, Cyprus (Kleinaki, Ishak, Arnaouti, Nikas).

Johannes A Vey (JA)

Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany (Vey, Awounvo).

Sinclair Awounvo (S)

Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany (Vey, Awounvo).

Angela Ishak (A)

From School of Medicine, European University Cyprus, Nicosia, Cyprus (Kleinaki, Ishak, Arnaouti, Nikas).
the Department of Internal Medicine, Henry Ford Health System, Detroit, Michigan (Ishak).

Maria Arnaouti (M)

From School of Medicine, European University Cyprus, Nicosia, Cyprus (Kleinaki, Ishak, Arnaouti, Nikas).

Han Suk Ryu (HS)

the Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea (Ryu).

Ilias P Nikas (IP)

From School of Medicine, European University Cyprus, Nicosia, Cyprus (Kleinaki, Ishak, Arnaouti, Nikas).
Medical School, University of Cyprus, Nicosia, Cyprus (Nikas).

Classifications MeSH